Rhythm EVP exercises RSUs into 12,875 shares
Rhythm Pharmaceuticals EVP exercises restricted stock units into shares Executive Vice President and Head of International Yann Mazabraud exercised restricted stock units that convert into common stock of Rhythm Pharmaceuticals.
Rhea-AI Filing Summary
Rhythm Pharmaceuticals EVP exercises restricted stock units into shares
Executive Vice President and Head of International Yann Mazabraud exercised restricted stock units that convert into common stock of Rhythm Pharmaceuticals. On April 1, 2026, he converted 10,375 and 2,500 restricted stock units into common shares at an exercise price of $0.00 per share.
Following these derivative exercises, his direct holdings increased to 66,030 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in four annual installments between April 2024 and April 2028, with no expiration date stated for the units.
Positive
- None.
Negative
- None.
Insider Trade Summary
12,875 shares exercised/converted
Exercise
3 txns
Insider
Mazabraud Yann
Role
EVP, Head of International
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 10,375 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 2,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,875 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 15,375 contracts (Direct);
Common Stock — 66,030 shares (Direct)
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2. The restricted stock units vest or have vested as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 1, 2026 and April 1, 2027. The restricted stock units have no expiration date.
- F3. The restricted stock units vest or have vested as to 25% of the total shares on each of April 15, 2025, April 1, 2026, April 1, 2027 and April 1, 2028. The restricted stock units have no expiration date.
Key Figures
RSUs exercised (grant 1): 10,375 units
RSUs exercised (grant 2): 2,500 units
Common shares acquired via exercise: 12,875 shares
+2 more
5 metrics
RSUs exercised (grant 1)
10,375 units
Restricted stock units converted on April 1, 2026
RSUs exercised (grant 2)
2,500 units
Additional restricted stock units converted on April 1, 2026
Common shares acquired via exercise
12,875 shares
Total underlying common stock from RSU exercises
Shares owned after transactions
66,030 shares
Direct common stock holdings following Form 4 transactions
Exercise price per share
$0.00 per share
Price for RSU-to-common stock conversion
Key Terms
Restricted Stock Units, derivative security, contingent right, vesting
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"Transaction code M is described as exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
vesting financial
"The restricted stock units vest or have vested as to 25% of the total shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Rhythm Pharmaceuticals (RYTM) report for Yann Mazabraud?
Rhythm Pharmaceuticals reported that EVP and Head of International Yann Mazabraud exercised restricted stock units into common stock. The Form 4 shows derivative exercises on April 1, 2026, increasing his directly held common shares with no open-market purchases or sales reported.
What type of securities did Yann Mazabraud exercise in the Rhythm Pharmaceuticals (RYTM) Form 4?
The filing shows Yann Mazabraud exercised Restricted Stock Units, a form of equity compensation. Each unit represents a contingent right to receive one share of Rhythm Pharmaceuticals common stock, which converts into shares as vesting conditions are satisfied.
How many restricted stock units did Yann Mazabraud convert into Rhythm Pharmaceuticals (RYTM) common stock?
On April 1, 2026, Mazabraud converted 10,375 and 2,500 restricted stock units into common stock. These derivative exercises are recorded at an exercise price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.
What is the vesting schedule of Yann Mazabraud’s restricted stock units at Rhythm Pharmaceuticals (RYTM)?
Footnotes explain that his restricted stock units vest in four annual installments of 25% each. One grant vests annually from April 14, 2024 through April 1, 2027, and another vests annually from April 15, 2025 through April 1, 2028, with no expiration date stated.
Does this Rhythm Pharmaceuticals (RYTM) Form 4 show any stock sales by Yann Mazabraud?
The Form 4 does not report any open-market stock sales by Yann Mazabraud. All transactions are coded as derivative exercises (code M), representing conversions of restricted stock units into common shares rather than buy or sell transactions in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
